MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen

Summary

The first results of Anti-Vascular Endothelial Growth Factor (VEGF) therapy were very promising and superior to established therapies. Three different substances (all of them applied intravitreally) are available, but comparative studies have not yet been conducted. In this pilot study, the safety (number of adverse events) and efficacy (distance acuity testing retinal thickness measurement) of Avastin and Macugen applied as monotherapy will be compared to a combined treatment of Avastin followed by Macugen used for retreatment. At least equal results of the combined therapy are expected.

Timeline

Start

2006-07

Primary completion

2008-12

Completion

2008-12

Drugs

Indications